Daina Graybosch
Stock Analyst at Leerink Partners
(1.34)
# 3,531
Out of 5,182 analysts
99
Total ratings
42.65%
Success rate
-6.06%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Daina Graybosch
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACLX Arcellx | Downgrades: Market Perform | $115 | $114.87 | +0.11% | 6 | Feb 24, 2026 | |
| IPSC Century Therapeutics | Downgrades: Market Perform | $7 → $2 | $2.27 | -11.89% | 5 | Nov 17, 2025 | |
| IPHA Innate Pharma | Downgrades: Market Perform | $10 → $2 | $1.46 | +36.99% | 11 | Sep 18, 2025 | |
| XLO Xilio Therapeutics | Initiates: Outperform | $28 | $8.46 | +230.97% | 1 | Aug 6, 2025 | |
| ADAG Adagene | Initiates: Outperform | $7 | $3.84 | +82.29% | 1 | Aug 6, 2025 | |
| SMMT Summit Therapeutics | Initiates: Underperform | $12 | $20.03 | -40.09% | 1 | Jun 11, 2025 | |
| MRK Merck & Co. | Maintains: Outperform | $136 → $119 | $120.15 | -0.96% | 19 | Jan 13, 2025 | |
| BOLT Bolt Biotherapeutics | Downgrades: Market Perform | $60 → $20 | $4.66 | +329.18% | 8 | May 15, 2024 | |
| NKTR Nektar Therapeutics | Maintains: Market Perform | $75 → $45 | $80.45 | -44.06% | 10 | Feb 24, 2023 | |
| FATE Fate Therapeutics | Maintains: Outperform | $62 → $10 | $1.31 | +663.36% | 7 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $38 | $22.39 | +69.72% | 2 | Nov 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $30 → $8 | $4.21 | +90.03% | 4 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $223 → $224 | $96.70 | +131.64% | 16 | Jul 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $2.29 | +1,210.04% | 1 | Jul 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $17 | $0.92 | +1,752.66% | 3 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $9 | $2.76 | +226.09% | 4 | Feb 25, 2022 |
Arcellx
Feb 24, 2026
Downgrades: Market Perform
Price Target: $115
Current: $114.87
Upside: +0.11%
Century Therapeutics
Nov 17, 2025
Downgrades: Market Perform
Price Target: $7 → $2
Current: $2.27
Upside: -11.89%
Innate Pharma
Sep 18, 2025
Downgrades: Market Perform
Price Target: $10 → $2
Current: $1.46
Upside: +36.99%
Xilio Therapeutics
Aug 6, 2025
Initiates: Outperform
Price Target: $28
Current: $8.46
Upside: +230.97%
Adagene
Aug 6, 2025
Initiates: Outperform
Price Target: $7
Current: $3.84
Upside: +82.29%
Summit Therapeutics
Jun 11, 2025
Initiates: Underperform
Price Target: $12
Current: $20.03
Upside: -40.09%
Merck & Co.
Jan 13, 2025
Maintains: Outperform
Price Target: $136 → $119
Current: $120.15
Upside: -0.96%
Bolt Biotherapeutics
May 15, 2024
Downgrades: Market Perform
Price Target: $60 → $20
Current: $4.66
Upside: +329.18%
Nektar Therapeutics
Feb 24, 2023
Maintains: Market Perform
Price Target: $75 → $45
Current: $80.45
Upside: -44.06%
Fate Therapeutics
Jan 6, 2023
Maintains: Outperform
Price Target: $62 → $10
Current: $1.31
Upside: +663.36%
Nov 3, 2022
Maintains: Outperform
Price Target: $40 → $38
Current: $22.39
Upside: +69.72%
Aug 29, 2022
Downgrades: Market Perform
Price Target: $30 → $8
Current: $4.21
Upside: +90.03%
Jul 29, 2022
Maintains: Outperform
Price Target: $223 → $224
Current: $96.70
Upside: +131.64%
Jul 18, 2022
Initiates: Outperform
Price Target: $30
Current: $2.29
Upside: +1,210.04%
May 11, 2022
Maintains: Outperform
Price Target: $18 → $17
Current: $0.92
Upside: +1,752.66%
Feb 25, 2022
Maintains: Outperform
Price Target: $16 → $9
Current: $2.76
Upside: +226.09%